<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877483</url>
  </required_header>
  <id_info>
    <org_study_id>2020-07-003C</org_study_id>
    <nct_id>NCT04877483</nct_id>
  </id_info>
  <brief_title>To Evaluate the Short-term and Long Term Efficacy of Acupuncture in Ocular and Oral Dryness Symptoms of Dry Eye Syndrome</brief_title>
  <official_title>To Evaluate the Short-term and Long Term Efficacy of Acupuncture in Ocular and Oral Dryness Symptoms of Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study wants to use a randomized, single-blind, controlled trial to evaluate the efficacy&#xD;
      of receiving acupuncture GB20 or GB20 plus BL2 on alleviating the ocular dryness symptom from&#xD;
      dry eye syndrome. Eighty dry eye syndrome subjects are randomized into 40 Group GB20 and 40&#xD;
      Group GB20 plus BL2 while both groups received acupuncture twice a week 8 weeks for efficacy&#xD;
      evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup&#xD;
      time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM&#xD;
      pulse diagnosis, and TCM heart rate variability for this purpose. And we also include 10&#xD;
      healthy control, and want to find the difference with the comparison between the dry eye&#xD;
      syndrome and healthy control. Through the multi-omics analysis for dry eye syndrome, we could&#xD;
      find the biomarker to differentiate dry eye syndrome and healthy control. In the future, this&#xD;
      work could be applied for screening and diagnosis of pre- dry eye syndrome, and this&#xD;
      integrated TCM with Western Medicine plan could be applied for the goal of holistic health&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method:&#xD;
&#xD;
      This study wants to use a randomized, single-blind, controlled trial to evaluate the efficacy&#xD;
      of receiving acupuncture GB20 or GB20 plus BL2 on alleviating the ocular dryness symptom from&#xD;
      dry eye syndrome. Eighty dry eye syndrome subjects are randomized into 40 Group GB20 and 40&#xD;
      Group GB20 plus BL2 while both groups received acupuncture twice a week 8 weeks for efficacy&#xD;
      evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup&#xD;
      time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM&#xD;
      pulse diagnosis, and TCM heart rate variability for this purpose. And we also include 10&#xD;
      healthy control, and want to find the difference with the comparison between the dry eye&#xD;
      syndrome and healthy control. Through the multi-omics analysis for dry eye syndrome, we could&#xD;
      find the biomarker to differentiate dry eye syndrome and healthy control. In the future, this&#xD;
      work could be applied for screening and diagnosis of pre- dry eye syndrome, and this&#xD;
      integrated TCM with Western Medicine plan could be applied for the goal of holistic health&#xD;
      care.&#xD;
&#xD;
      Expected Results:&#xD;
&#xD;
        1. To evaluate the difference among TCM pattern, TCM tongue diagnosis, TCM pulse diagnosis,&#xD;
           heart rate variability, proteomics and oral microbiota for dry eye syndrome and healthy&#xD;
           control.&#xD;
&#xD;
        2. Integrated functional multi-omics for dry eye syndrome and healthy control.&#xD;
&#xD;
        3. To evaluate the efficacy of GB20 plus BL2 for dry eye syndrome.&#xD;
&#xD;
        4. To evaluate the efficacy of GB20 for dry eye syndrome.&#xD;
&#xD;
        5. To evaluate the efficacy of BL2 for dry eye syndrome.&#xD;
&#xD;
      Keywords: Dry eye syndrome, Xerophthalmia, Acupuncture, GB20, BL2, Proteomics, Oral&#xD;
      microbiota&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Schirmer's test</measure>
    <time_frame>one year</time_frame>
    <description>Schirmer's test is a tool for evaluating aqueous tear production among the dry eye syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OSDI(Ocular Surface Disease Index)</measure>
    <time_frame>one year</time_frame>
    <description>OSDI(Ocular Surface Disease Index) is a tool to rate the severity of dry eye disease among the dry eye syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TCM pattern</measure>
    <time_frame>one year</time_frame>
    <description>TCM pattern is a tool for detecting the constitution among the Dry eye syndrome (DES) and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCM tongue diagnosis</measure>
    <time_frame>one year</time_frame>
    <description>TCM tongue diagnosis is a tool for detecting tongue expression among the Dry eye syndrome (DES) and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (HRV)</measure>
    <time_frame>one year</time_frame>
    <description>Heart rate variability (HRV) is a tool for detecting ratio betwee n High-frequency (HF) activity and low-frequency (LF) activity among the Dry eye syndrome (DES) and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCM pulse diagnosis</measure>
    <time_frame>one year</time_frame>
    <description>TCM tongue diagnosis is a tool for detecting tongue expression pulse pattern among the Dry eye syndrome (DES) and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-GSI(6-Item Gastrointestinal Severity Index)</measure>
    <time_frame>one year</time_frame>
    <description>6-item GI Severity Index (6-GSI) questionnaire is an tool for assessing gastrointestinal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36(36-Item Short Form Survey )</measure>
    <time_frame>one year</time_frame>
    <description>SF-36 is a tool for evaluating Health-Related Quality of Life among the Dry eye syndrome (DES).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)</measure>
    <time_frame>one year</time_frame>
    <description>ESSPRI is a tool for evaluating the symptoms of SJS among the dry eye syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear breakup time (TBUT)</measure>
    <time_frame>one year</time_frame>
    <description>Tear breakup time (TBUT) is a clinical test used to assess for evaporative dry eye disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-genome genotyping(TWBv2.0)</measure>
    <time_frame>one year</time_frame>
    <description>By using the Whole-genome genotyping(TWBv2.0) of the immune-relate gene(RF5,TNIP1 (TNFAIP3),FCGR2B,TNF,LTA,NFKBIA,STAT4,IL-1β,IL-1R,IL-6,IL-6R,IL-8,IL-8R,IL-10,IL-10R,IL-12,IL-12R,IL-17,IL-17R,IL-18,IL-18R,IL-23,IL-23R,IL-27,IL-27R,TGF-β1,IFN-α,IFN-αR,IFN-γ,IFN-γR,TNFRSF4,BLK,CXCR5,CXCL10 to find the difference with the comparison between the dry eye syndrome and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>one year</time_frame>
    <description>By using the Proteomics analysis of LYS-C,LACTO,LIPOC-1,ALB,clusterin,IL-4,IL-5,FGF-4,pappalysin-1,C-reactive protein,apolipo-protein A-II,Con A-bound ITIH3,CTNNA3,PTPN6 and RAC2 to find the difference with the comparison between the dry eye syndrome and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiota</measure>
    <time_frame>one year</time_frame>
    <description>By using the Oral microbiota analysis to find the difference with the comparison between the dry eye syndrome and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biochemical analysis</measure>
    <time_frame>one year</time_frame>
    <description>By using the blood biochemical analysis of BUN,Cre,AST,ALT,CRP and ESR to evaluate the liver function and renal function among the Dry eye syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine biomarkers</measure>
    <time_frame>one year</time_frame>
    <description>By using cytokine biomarkers analysis of IL-17,MMP-9,BAFF and BCMA to find the difference with the comparison between the dry eye syndrome and healthy control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBC(complete blood count)</measure>
    <time_frame>one year</time_frame>
    <description>A complete blood count (CBC) is a blood test used to evaluate overall health among the Dry eye syndromes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <condition>Xerophthalmia</condition>
  <arm_group>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy control group will not received any treatment. And we could use the proteomics, oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Proteomics</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the Proteomics analysis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oral microbiota</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Schirmer's test</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tear breakup time</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6-GSI(six item Gastrointestinal Severity Index)</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the 6-GSI test.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OSDI(Ocular Surface Disease Index)</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the OSDI test.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TCM pattern</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Traditional Chinese Medicine (TCM) tongue diagnosis</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TCM pulse diagnosis</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TCM heart rate variability</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the ESSPRI.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Whole-genome genotyping(TWBv2.0)</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cytokine markers</intervention_name>
    <description>Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood biochemical analysis</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>complete blood count (CBC)</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SF-36(36-Item Short Form Survey )</intervention_name>
    <description>Group GB20 and Group GB20 plus BL2 will take the SF-36 test.</description>
    <arm_group_label>Group GB20</arm_group_label>
    <arm_group_label>Group GB20 plus BL2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged between 20 and 75 years&#xD;
&#xD;
          2. Schirmer's test less than 10 mm/5 min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. With eye inflammation or infectious eye disease&#xD;
&#xD;
          3. Accepted operation of eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Ching-Mao, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang Ching-Mao, M.D., Ph.D.</last_name>
    <phone>886-28757453</phone>
    <phone_ext>333</phone_ext>
    <email>magicbjp@gmail.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dry eye syndromes</keyword>
  <keyword>Xerophthalmia</keyword>
  <keyword>acupuncture</keyword>
  <keyword>GB20</keyword>
  <keyword>BL2</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Oral microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Xerophthalmia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

